Timolol Eye Drops Manufacturer in India

Yes. Timolol is listed on the WHO Model List of Essential Medicines for the management of glaucoma and ocular hypertension. This designation drives substantial institutional and government procurement demand globally — particularly in national blindness prevention programmes across Africa, South Asia and the Middle East where glaucoma is a leading cause of preventable irreversible blindness. 9M India manufactures Timolol at scale for this institutional demand.

Timolol is a non-selective beta-adrenergic blocker that reduces aqueous humour production by the ciliary body epithelium — the primary mechanism for lowering intraocular pressure (IOP). It reduces IOP by approximately 25–30% from baseline, achieving maximal effect within 1–2 hours and sustained IOP reduction over 24 hours with twice-daily dosing. It remains one of the most cost-effective IOP-lowering agents available.

Timolol 0.25% is the starting dose used in patients who may be sensitive to beta-blockade — including elderly patients, those with mild respiratory conditions and first-time users. Timolol 0.5% is the standard therapeutic dose providing greater IOP reduction for patients requiring more aggressive pressure control. Both strengths are available from 9M India and many prescribers start with 0.25% before stepping up to 0.5% if needed.

Timolol eye drops are contraindicated in patients with asthma, severe COPD, sinus bradycardia, second or third degree AV block, and overt heart failure — due to systemic absorption of the beta-blocker through the nasolacrimal drainage system. Nasolacrimal occlusion (pressing the inner corner of the eye after instillation) reduces systemic absorption significantly. These are clinical prescribing considerations — relevant context for market positioning and patient information materials.

Yes. 9M India manufactures Timolol in combination with Dorzolamide (Timolol + Dorzolamide — beta- blocker + carbonic anhydrase inhibitor), Brimonidine (Timolol + Brimonidine — beta-blocker + alpha-2 agonist) and Latanoprost (Timolol + Latanoprost — beta-blocker + prostaglandin analogue). Fixed-dose combination antiglaucoma eye drops improve compliance by reducing the number of daily drops for patients on multiple glaucoma medications.

Documentation available includes WHO-GMP Certificate, DCGI Manufacturing Licence, CoPP, batch- wise CoA (sterility, particulate matter, pH, assay, preservative content), ICH Zone IVb stability data and CTD/ACTD dossiers on request. As a WHO Essential Medicine, Timolol eye drops are among our most established export formulations with dossiers available for multiple markets across the Middle East, Africa, CIS and ASEAN.

Timolol maleate is available in standard ophthalmic solution (0.25% and 0.5%) and as a gel-forming solution (Timolol GFS 0.1%) from 9M India. The gel-forming formulation gels on contact with the tear film, providing sustained drug release and once-daily dosing — improving compliance. Please contact our team for availability and specifications of the gel-forming formulation.